IMMUNOCORE HOLDINGS PLC

(IMCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immunocore : Corporate Presentation - January 2022

01/10/2022 | 06:48am EDT

Corporate Presentation

40th Annual J.P. Morgan Healthcare Conference January 2022

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this presentation include but are not limited to, statements about the Company's proposed regulatory plans for tebentafusp, the efficacy, safety and therapeutic potential of tebentafusp, the expected timing of a BLA review and action date for tebentafusp for the treatment of mUM, the potential approval and commercial launch of tebentafusp for mUM, the design, progress, timing, scope and results of the Company's clinical trials including IMC-C103C,IMC-F106C,IMC-I109V and IMC-M113V, the anticipated achievement of upcoming clinical milestones, the potential benefit of Breakthrough Therapy Designation or Orphan Drug Designation for tebentafusp the design, progress, timing, scope and results of the Company's clinical trials including IMC-C103C and tebentafusp; the potential clinical benefit of the Company's product candidates; the timing and outcome of discussions with regulatory authorities; and the success of any licensing or partnering opportunities. Each of these forward-looking statements involves risks and uncertainties. These statements are based on the Company's current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward- looking statements. Factors that may cause actual results to differ materially from these forward-looking statements include the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more clinical outcomes may materially change as patient enrollment continues and or more patient data becomes available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are discussed in Immunocore's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Immunocore's business and the overall global economy. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Except to the extent required by law, Immunocore undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Immunocore's own internal estimates and research. While Immunocore believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third - party sources.

2

© 2022 Immunocore. Not for further reproduction or distribution.

Harnessing the immune system to fight disease

with targeted, off-the-shelf, bispecific, soluble T cell receptors (TCRs)

Click to add text

T-cell receptor

T-cell receptor

ImmTAC

3

© 2022 Immunocore. Not for further reproduction or distribution.

Immunocore: Pioneering TCR therapeutics

Leader in off-the-shelf bispecific T-cell engagers

First TCR to demonstrate monotherapy overall survival (OS) benefit in solid tumor

Clinically-validated platform moving to commercialization in mUM1

Potential first FDA approval for a TCR therapeutic

Pipeline with potential in multiple indications / therapeutic areas

Oncology (tebentafusp, PRAME, MAGE-A4), infectious and autoimmune diseases 5 clinical stage programs

1. Metastatic uveal melanoma

4

© 2022 Immunocore. Not for further reproduction or distribution.

Our team

Proven track record with over 25 new medicines for patients

Bahija Jallal

Brian Di Donato

CEO

CFO & Head of Strategy

IMFINZI, FASENRA, LUMOXITI, SELIQ,

QAIV, SAPHNELO

Andy Hooker

JoAnn Suzich

VP, CMC & Supply Chain

Head of Research

CIMZIA

SYNAGIS, FLUMIST, VLP

technology for HPV vaccines

David Berman

Mohammed Dar

Head of R&D

CMO

YERVOY, EMPLICITI, LUMOXITI, IMFINZI

VOTRIENT, IMFINZI, LUMOXITI

Mark Moyer

Ralph Torbay

Head of Regulatory

Head of Commercial

YERVOY, OPDIVO, TAXOTERE, ZOLADEX,

IMFINZI, TAGRISSO, CALQUENCE, GLEEVEC,

PLAVIX, JEVTANA, ELOXATIN

TASIGNA, ARZERRA, FARYDAK

5

© 2022 Immunocore. Not for further reproduction or distribution.

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Immunocore Holdings plc published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 January 2022 11:47:02 UTC.


© Publicnow 2022
All news about IMMUNOCORE HOLDINGS PLC
05/11Immunocore Holdings Q1 Net Loss Narrows as Revenue Rises
MT
05/11Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, ..
CI
05/11Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
GL
04/18IMMUNOCORE : Corporate Presentation - April 2022
PU
04/07Immunocore to present at the 21st Annual Needham Healthcare Conference
AQ
04/04IMMUNOCORE : European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unr..
PU
04/04Immunocore Wins European Regulatory Ok of Kimmtrak for Unresectable or Metastatic Uveal..
MT
04/04European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable ..
GL
04/04European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable ..
GL
04/04European Commission Approves Immunocore Holdings plc's KIMMTRAK (Tebentafusp) for the T..
CI
More news
Analyst Recommendations on IMMUNOCORE HOLDINGS PLC
More recommendations
Financials
Sales 2022 83,5 M 104 M 104 M
Net income 2022 -89,2 M -111 M -111 M
Net cash 2022 226 M 283 M 283 M
P/E ratio 2022 -11,8x
Yield 2022 -
Capitalization 1 020 M 1 275 M 1 275 M
EV / Sales 2022 9,51x
EV / Sales 2023 10,8x
Nbr of Employees 324
Free-Float 37,6%
Chart IMMUNOCORE HOLDINGS PLC
Duration : Period :
Immunocore Holdings plc Technical Analysis Chart | IMCR | US45258D1054 | MarketScreener
Technical analysis trends IMMUNOCORE HOLDINGS PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2 323,56 GBX
Average target price 4 291,74 GBX
Spread / Average Target 84,7%
EPS Revisions
Managers and Directors
Bahija Jallal Chief Executive Officer & Director
Brian R. DiDonato Chief Financial Officer & Head-Strategy
John Irving Bell Chairman
David Berman Head-Research & Development
Travis Coy Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOCORE HOLDINGS PLC-15.16%1 280
MODERNA, INC.-43.55%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-28.50%37 337
SEAGEN INC.-7.74%26 323
ICON PUBLIC LIMITED COMPANY-30.82%16 524